01 / Vendor Profile
ANTAGEN PHARMACEUTICALS, INC. Federal Contracts and Awards
UEI HXD6EFH2ND57 · CAGE 59GJ1
Federal contract activity attributed to this vendor identity across FY 2019–FY 2025. Obligations are FPDS accounting transactions, not company revenue.
02 / Federal Business Size
Federal contract market at a glance
Measured consistently across FY 2019–FY 2025.
Across FY 2019–FY 2025, FPDS records attribute $1.80M in net contract obligations to ANTAGEN PHARMACEUTICALS, INC. across 17 contract actions. Net obligations include positive obligations and later deobligations recorded during the same period.
03 / Spending Trend
ANTAGEN PHARMACEUTICALS, INC. contract spending by year
Annual net obligations show whether recorded federal business expanded or contracted, while actions and customer counts show the breadth of that activity.
Total obligations$0
FY 2024ObligationsHistorical spending range
| Fiscal year | Obligations | Actions | Federal customers | Change |
|---|---|---|---|---|
| FY 2019 | $599.9K | 1 | 1 | — |
| FY 2020 | $600.0K | 3 | 1 | +0.0% |
| FY 2021 | $0 | 2 | 1 | −100.0% |
| FY 2022 | $600.0K | 6 | 2 | — |
| FY 2023 | $0 | 4 | 1 | −100.0% |
| FY 2024 | $0 | 1 | 1 | — |
04 / Federal Customers
Which federal agencies buy from ANTAGEN PHARMACEUTICALS, INC.?
Ranked by net obligations during FY 2019–FY 2025.
| Agency | Code | Obligations | Actions | Vendor share |
|---|---|---|---|---|
| 7529 | $1.80M | 16 | 100.0% | |
| 7523 | $0 | 1 | 0.0% |
05 / Contracting Offices
Which contracting offices buy from ANTAGEN PHARMACEUTICALS, INC.?
Ranked by net obligations during FY 2019–FY 2025.
| Office | Code | Agency | Obligations | Actions | Vendor share |
|---|---|---|---|---|---|
| 75N930 | NATIONAL INSTITUTES OF HEALTH | $1.80M | 16 | 100.0% | |
| 75D301 | CENTERS FOR DISEASE CONTROL AND PREVENTION | $0 | 1 | 0.0% |
06 / Top NAICS Industries
Which industries define this vendor’s federal work?
| NAICS | Description | Obligations | Actions | Customers | Share |
|---|---|---|---|---|---|
| 541714 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) | $900.0K | 10 | 1 | 50.0% |
| 541715 | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) | $899.9K | 6 | 1 | 50.0% |
| 541711 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY | $0 | 1 | 1 | 0.0% |
07 / Top Product and Service Codes
What products and services does the government buy from this vendor?
08 / Competition Pattern
How was ANTAGEN PHARMACEUTICALS, INC.’s federal work competed?
Competition categories describe the procurement path recorded on the underlying contract actions.
09 / Recent Contract Awards
What contract actions were recorded most recently for ANTAGEN PHARMACEUTICALS, INC.?
The latest recorded PIIDs connect this profile to the underlying federal award search.
| Award / PIID | Signed | Obligation | Agency / office | NAICS | PSC |
|---|---|---|---|---|---|
| 75N93020C00042 | Nov 1, 2023 | $0 | NATIONAL INSTITUTES OF HEALTH NATIONAL INSTITUTES OF HEALTH NIAID | 541714 | AN12 |
10 / Interpreting the Profile
How should you evaluate ANTAGEN PHARMACEUTICALS, INC. as a federal contractor?
Read obligations, customers, markets, competition, and individual awards together. A large historical total indicates federal scale, but it does not by itself describe current backlog, commercial revenue, profitability, or future opportunity.
Separate obligations from revenue
FPDS obligations are government accounting actions and may include later deobligations.
Follow customer concentration
Agency and office concentration reveals where the vendor’s federal relationships are strongest.
Test market overlap
NAICS and PSC shares show whether the vendor competes in the same markets as your company.
Inspect the awards
Open the PIIDs to verify dates, offices, classifications, and transaction history.